|
Apr 14, 2021
|
BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema
|
|
|
Apr 07, 2021
|
BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference
|
|
|
Mar 22, 2021
|
BioCryst’s Oral Factor D Inhibitor, BCX9930, Advancing to Pivotal Trials in PNH Following Successful Proof of Concept Trial
|
|
|
Mar 19, 2021
|
BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer
|
|
|
Mar 15, 2021
|
BioCryst to Host Virtual R&D Day on March 22, 2021
|
|
|
Mar 11, 2021
|
Early Access to BioCryst’s Berotralstat Granted for HAE Patients in France
|
|
|
Mar 02, 2021
|
BioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
|
|
|
Feb 25, 2021
|
BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
|
|
|
Feb 25, 2021
|
BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones
|
|
|
Feb 18, 2021
|
BioCryst to Present at Upcoming Investor Conferences
|
|
